IP Library › Granted Patent US 12,496,341
Granted Patent B2
US 12,496,341 · App. 18/423,395 · Granted Dec 16, 2025

Methods for reducing anergy in lymphocytes using modulators of MYC

Inventors: Yosef Refaeli (Denver, CO); Brian Curtis Turner (Denver, CO)
Assignee: HTYR Acquisition LLC
A61K39/39C07K14/001C07K14/47C07K14/82A61K38/00C07K2319/02C07K2319/21Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,341
App. No.
18/423,395
Granted
Dec 16, 2025
Kind
B2
Abstract

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.

Claims (12)

1 . A method for reversing anergy in one or more anergic lymphocytes in a subject in need thereof, comprising administering a MYC fusion peptide to the subject, wherein the fusion peptide comprises:

(i) a transporter peptide sequence; and

(ii) a MYC polypeptide sequence.

2 . The method of claim 1 , wherein the MYC fusion peptide has Formula (I):

transporter peptide sequence-MYC polypeptide sequence.

3 . The method of claim 1 , wherein the MYC fusion peptide has Formula (II): transporter peptide sequence-X-MYC polypeptide sequence, wherein -X- is a molecule that links the transporter peptide sequence and the MYC polypeptide sequence.

4 . The method of claim 1 , wherein the MYC fusion peptide has Formula (II): transporter peptide sequence-X-MYC polypeptide sequence, wherein X is at least one amino acid.

5 . The method of claim 1 , wherein the one or more anergic lymphocytes comprises an anergic B cell or an anergic T cell.

6 . The method of claim 1 , wherein the MYC fusion peptide is formulated for oral administration, parenteral administration, intranasal administration, buccal administration, rectal administration, or intravenous administration.

7 . The method of claim 1 , wherein the MYC fusion peptide is formulated for intramuscular or subcutaneous administration.

8 . The method of claim 1 , wherein the MYC fusion peptide is formulated for topical or transdermal administration.

9 . The method of claim 1 , wherein the MYC fusion peptide is formulated as a delayed release formulation or as an extended-release formulation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2024
From: TAIGA BIOTECHNOLOGIES, INC.
To: TAIGA BIOTECHNOLOGIES (ABC), LLC
Reel/Frame 067933/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2024
From: REFAELI, YOSEF; TURNER, BRIAN CURTIS
To: TAIGA BIOTECHNOLOGIES, INC.
Reel/Frame 067900/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2024
From: TAIGA BIOTECHNOLOGIES (ABC), LLC, AS ASSIGNEE FOR THE BENEFIT OF CREDITORS OF TAIGA BIOTECHNOLOGIES, INC.
To: HTYR ACQUISITION LLC
Reel/Frame 067900/0792 →
Continuity (8)
Continuation 17750029 · May 20, 2022
Continuation 16742150 · Jan 14, 2020
Continuation 15717675 · Sep 27, 2017
Continuation 14461105 · Aug 15, 2014
Continuation 13777967 · Feb 26, 2013
Continuation 12550166 · Aug 28, 2009
Provisional Application 61092708 · Aug 28, 2008
Related Publication 20240156957A1 · May 16, 2024
References Cited (400)
US 4900322A · Adams · 1990 [cited by applicant]
US 4963489A · Naughton et al. · 1990 [cited by applicant]
US 5289858A · Grabenkort · 1994 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5652122A · Frankel et al. · 1997 [cited by applicant]
US 5670617A · Frankel et al. · 1997 [cited by applicant]
US 5674980A · Frankel et al. · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5747641A · Frankel et al. · 1998 [cited by applicant]
US 5804604A · Frankel et al. · 1998 [cited by applicant]
US 5811301A · Cameron · 1998 [cited by applicant]
US 5824837A · Chen et al. · 1998 [cited by applicant]
US 5843728A · Seed et al. · 1998 [cited by applicant]
US 5847082A · Rother et al. · 1998 [cited by applicant]
US 5849288A · Reisner · 1998 [cited by applicant]
US 5851828A · Seed et al. · 1998 [cited by applicant]
US 5912170A · Seed et al. · 1999 [cited by applicant]
US 6004811A · Seed et al. · 1999 [cited by applicant]
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 6284240B1 · Seed et al. · 2001 [cited by applicant]
US 6358739B1 · Baetge et al. · 2002 [cited by applicant]
US 6392013B1 · Seed et al. · 2002 [cited by applicant]
US 6410014B1 · Seed et al. · 2002 [cited by applicant]
US 6451558B1 · Cooke et al. · 2002 [cited by applicant]
US 6451601B1 · Baetge et al. · 2002 [cited by applicant]
US 6645501B2 · Dowdy · 2003 [cited by applicant]
US 6753162B1 · Seed et al. · 2004 [cited by applicant]
US 7135287B1 · Lonberg et al. · 2006 [cited by applicant]
US 7311920B1 · Devico et al. · 2007 [cited by applicant]
US 7582745B2 · Sah et al. · 2009 [cited by applicant]
US 7767453B2 · Zhang et al. · 2010 [cited by applicant]
US 8034334B2 · Dudley et al. · 2011 [cited by applicant]
US 8211422B2 · Eshhar et al. · 2012 [cited by applicant]
US 8481492B2 · Edenhofer et al. · 2013 [cited by applicant]
US 8637307B2 · June et al. · 2014 [cited by applicant]
US 8697854B2 · Schendel et al. · 2014 [cited by applicant]
US 8784825B2 · Refaeli et al. · 2014 [cited by applicant]
US 8828723B2 · Refaeli et al. · 2014 [cited by applicant]
US 8986702B2 · Refaeli et al. · 2015 [cited by applicant]
US 9150831B2 · Cambier et al. · 2015 [cited by applicant]
US 9169462B2 · Refaeli et al. · 2015 [cited by applicant]
US 9365825B2 · Turner et al. · 2016 [cited by applicant]
US 9775897B2 · Refaeli et al. · 2017 [cited by applicant]
US 9789135B2 · Turner et al. · 2017 [cited by applicant]
US 10087420B2 · Turner et al. · 2018 [cited by applicant]
US 10149898B2 · Refaeli et al. · 2018 [cited by applicant]
US 10442853B2 · Refaeli et al. · 2019 [cited by applicant]
US 10760055B2 · Cambier et al. · 2020 [cited by applicant]
US 10864259B2 · Refaeli et al. · 2020 [cited by applicant]
US 11116796B2 · Turner et al. · 2021 [cited by applicant]
US 11369678B2 · Refaeli et al. · 2022 [cited by applicant]
US 20010049393A1 · Coller et al. · 2001 [cited by applicant]
US 20020055478A1 · Faris et al. · 2002 [cited by applicant]
US 20020076787A1 · Baetge et al. · 2002 [cited by applicant]
US 20020098166A1 · Havemann et al. · 2002 [cited by applicant]
US 20020155502A1 · Balint et al. · 2002 [cited by applicant]
US 20030072794A1 · Boulikas · 2003 [cited by applicant]
US 20030138859A1 · Barbera-Guillem et al. · 2003 [cited by applicant]
US 20030220286A1 · Abruzzese et al. · 2003 [cited by applicant]
US 20040224402A1 · Bonyhadi et al. · 2004 [cited by applicant]
US 20050220705A1 · Brooks et al. · 2005 [cited by applicant]
US 20050281816A1 · Lamping et al. · 2005 [cited by applicant]
US 20060068369A1 · Coelho et al. · 2006 [cited by applicant]
US 20060068469A1 · Payne et al. · 2006 [cited by applicant]
US 20060115898A1 · Zhang et al. · 2006 [cited by applicant]
US 20060154331A1 · Avidan et al. · 2006 [cited by applicant]
US 20060156422A1 · Dalrymple et al. · 2006 [cited by applicant]
US 20060222657A1 · Dowdy et al. · 2006 [cited by applicant]
US 20070011753A1 · Ito et al. · 2007 [cited by applicant]
US 20070047583A1 · Assa et al. · 2007 [cited by applicant]
US 20070067854A1 · Habu et al. · 2007 [cited by applicant]
US 20070082397A1 · Hasson et al. · 2007 [cited by applicant]
US 20070093420A1 · Yeomans et al. · 2007 [cited by applicant]
US 20070098715A1 · Ettenberg et al. · 2007 [cited by applicant]
US 20070116691A1 · Cambier et al. · 2007 [cited by applicant]
US 20070130628A1 · Brown · 2007 [cited by applicant]
US 20070248618A1 · Cohen · 2007 [cited by applicant]
US 20080050396A1 · Andersen et al. · 2008 [cited by applicant]
US 20090291094A1 · Refaeli et al. · 2009 [cited by applicant]
US 20100047217A1 · Refaeli et al. · 2010 [cited by applicant]
US 20100055129A1 · Refaeli et al. · 2010 [cited by applicant]
US 20100233804A1 · Zhou et al. · 2010 [cited by applicant]
US 20100279351A1 · Refaeli et al. · 2010 [cited by applicant]
US 20100297763A1 · Cambier et al. · 2010 [cited by applicant]
US 20110218210A1 · Refaeli et al. · 2011 [cited by applicant]
US 20120003189A1 · Pelus et al. · 2012 [cited by applicant]
US 20120025156A1 · Roodenburg et al. · 2012 [cited by applicant]
US 20120027792A1 · Pavlakis et al. · 2012 [cited by applicant]
US 20120244133A1 · Rosenberg et al. · 2012 [cited by applicant]
US 20130177586A1 · Refaeli et al. · 2013 [cited by applicant]
US 20140109246A1 · Jimeno et al. · 2014 [cited by applicant]
US 20140255369A1 · Turner et al. · 2014 [cited by applicant]
US 20140356392A1 · Refaeli et al. · 2014 [cited by applicant]
US 20150164950A1 · Turner et al. · 2015 [cited by applicant]
US 20150218515A1 · Altrichter et al. · 2015 [cited by applicant]
US 20170044500A1 · Cooper et al. · 2017 [cited by applicant]
US 20180036396A1 · Refaeli et al. · 2018 [cited by applicant]
US 20190060434A1 · Refaeli et al. · 2019 [cited by applicant]
US 20200215188A1 · Refaeli et al. · 2020 [cited by applicant]
US 20210121550A1 · Refaeli et al. · 2021 [cited by applicant]
AU 2762802A · 2002 [cited by applicant]
AU 2006304392A1 · 2007 [cited by applicant]
CA 2584738A1 · 2006 [cited by applicant]
CA 2626525A1 · 2007 [cited by applicant]
CN 1206044A · 1999 [cited by applicant]
CN 1357620A · 2002 [cited by applicant]
CN 1659187A · 2005 [cited by applicant]
CN 101045914A · 2007 [cited by applicant]
CN 101330830A · 2008 [cited by applicant]
CN 102027105A · 2011 [cited by applicant]
CN 102083960A · 2011 [cited by applicant]
CN 102083970A · 2011 [cited by applicant]
CN 103998604A · 2014 [cited by applicant]
CN 104353066A · 2015 [cited by applicant]
CN 104640551A · 2015 [cited by applicant]
EP 0213469A2 · 1987 [cited by applicant]
EP 1103615A1 · 2001 [cited by applicant]
EP 1357184A2 · 2003 [cited by applicant]
EP 1792627A1 · 2007 [cited by applicant]
GB 2387599A · 2003 [cited by applicant]
JP 2000189157A · 2000 [cited by applicant]
JP 2001020959A · 2001 [cited by applicant]
JP 2001501909A · 2001 [cited by applicant]
JP 2001518300A · 2001 [cited by applicant]
JP 2002541786A · 2002 [cited by applicant]
JP 2003513672A · 2003 [cited by applicant]
JP 2003514565A · 2003 [cited by applicant]
JP 2003265189A · 2003 [cited by applicant]
JP 2004519245A · 2004 [cited by applicant]
JP 2005523012A · 2005 [cited by applicant]
JP 2005525085A · 2005 [cited by applicant]
JP 2005232148A · 2005 [cited by applicant]
JP 2005527211A · 2005 [cited by applicant]
JP 2006519781A · 2006 [cited by applicant]
JP 2009511081A · 2009 [cited by applicant]
JP 2011528567A · 2011 [cited by applicant]
JP 2012501347A · 2012 [cited by applicant]
JP 2014527980A · 2014 [cited by applicant]
JP 2015524415A · 2015 [cited by applicant]
JP 2015525209A · 2015 [cited by applicant]
JP 2016510996A · 2016 [cited by applicant]
JP 2017513498A · 2017 [cited by applicant]
JP 6167130B2 · 2017 [cited by applicant]
JP 6484293 · 2019 [cited by applicant]
JP 6655050B2 · 2020 [cited by applicant]
WO 8603780A1 · 1986 [cited by applicant]
WO 9215322A1 · 1992 [cited by applicant]
WO 9404686A1 · 1994 [cited by applicant]
WO 9419465A2 · 1994 [cited by applicant]
WO 9514078A1 · 1995 [cited by applicant]
WO 9810058A1 · 1998 [cited by applicant]
WO 9852614A2 · 1998 [cited by applicant]
WO 9916884A1 · 1999 [cited by applicant]
WO 9945962A1 · 1999 [cited by applicant]
WO 9953023A1 · 1999 [cited by applicant]
WO 9953028A1 · 1999 [cited by applicant]
WO 0009669A1 · 2000 [cited by applicant]
WO 0061617A2 · 2000 [cited by applicant]
WO 0062067A1 · 2000 [cited by applicant]
WO 0134824A2 · 2001 [cited by applicant]
WO 0138548A2 · 2001 [cited by applicant]
WO 02057436A2 · 2002 [cited by applicant]
WO 02074968A1 · 2002 [cited by applicant]
WO 03008630A2 · 2003 [cited by applicant]
WO 03033701A1 · 2003 [cited by applicant]
WO 03038057A2 · 2003 [cited by applicant]
WO 03039462A2 · 2003 [cited by applicant]
WO 03057171A2 · 2003 [cited by applicant]
WO 03089580A2 · 2003 [cited by applicant]
WO 03089630A1 · 2003 [cited by applicant]
WO 03094849A2 · 2003 [cited by applicant]
WO 03097675A1 · 2003 [cited by applicant]
WO 2004033685A1 · 2004 [cited by applicant]
WO 2004035535A2 · 2004 [cited by applicant]
WO 2004044004A2 · 2004 [cited by applicant]
WO 2004050885A2 · 2004 [cited by applicant]
WO 2004050895A2 · 2004 [cited by applicant]
WO 2004074322A1 · 2004 [cited by applicant]
WO 2004084805A2 · 2004 [cited by applicant]
WO 2005014785A2 · 2005 [cited by applicant]
WO 2005049073A2 · 2005 [cited by applicant]
WO 2005084158A2 · 2005 [cited by applicant]
WO 2005113595A2 · 2005 [cited by applicant]
WO 2005114215A2 · 2005 [cited by applicant]
WO 2006000830A2 · 2006 [cited by applicant]
WO 2006032876A1 · 2006 [cited by applicant]
WO 2006116512A1 · 2006 [cited by applicant]
WO 2006125962A2 · 2006 [cited by applicant]
WO 2007047583A2 · 2007 [cited by applicant]
WO 2007067183A1 · 2007 [cited by applicant]
WO 2008038002A2 · 2008 [cited by applicant]
WO 2008039818A2 · 2008 [cited by applicant]
WO 2008112922A2 · 2008 [cited by applicant]
WO 2009059304A2 · 2009 [cited by applicant]
WO 2009139930 · 2009 [cited by applicant]
WO 2010011664A1 · 2010 [cited by applicant]
WO 2010025421A2 · 2010 [cited by applicant]
WO 2011100477A2 · 2011 [cited by applicant]
WO 2012055170A1 · 2012 [cited by applicant]
WO 2013039889A1 · 2013 [cited by applicant]
WO 2013166321A1 · 2013 [cited by applicant]
WO 2014018863A1 · 2014 [cited by applicant]
WO 2014039908A1 · 2014 [cited by applicant]
WO 2014083173A1 · 2014 [cited by applicant]
WO 2014133567A1 · 2014 [cited by applicant]
WO 2014133568A1 · 2014 [cited by applicant]
WO 2014164606A1 · 2014 [cited by applicant]
WO 2016105542A2 · 2016 [cited by applicant]
WO 2017059319A2 · 2017 [cited by applicant]
WO 2017123978A1 · 2017 [cited by applicant]
WO 2018104909A2 · 2018 [cited by applicant]
Bird et al., PLoS ONE, Aug. 29, 2014, 9(8): e105525. doi: 10.1371/journal.pone.0105525. (Year: 2014). [cited by examiner]
Ju et al., “Anti-apoptotic therapy with a Tat fusion protein against excitotoxic insults in vitro and in vivo”, Experimental Neurology, vol. 210, No. 2, 2008, pp. 602-607, DOI: 10.1016/j.expneurol.2007.12.008 (6 pages). [cited by applicant]
Kaptein et al., “Anti-IgM-mediated Regulation of c-myc and Its Possible Relationship to Apoptosis”, The Journal of Biological Chemistry, vol. 271, No. 31, Aug. 2, 1996, pp. 18875-18884 (11 pages). [cited by applicant]
Karon et al., “Temporal sequence of major biochemical events during Blood Bank storage of packed red blood cells”, Blood Transfusion, vol. 10, 2012, pp. 453-461, DOI: 10.2450/2012.0099-11 (9 oaaes). [cited by applicant]
Kashio et al., “A Protein Derived From the Fusion of TAT Peptide and FNK, a Bcl-XL Derivative, Prevents Cochlear Hair Cell Death From Aminoglycoside Ototoxicity In Vivo”, Journal of Neuroscience Research, vol. 85, No. 7… [cited by applicant]
Kelso et al., “Survival of the Myeloid Progenitor Cell Line FDC-P1 is Prolonged by Interferon-gamma or Interleukin-4”, Growth Factors, vol. 6, No. 3, 1992, pp. 233-242 (10 pages). [cited by applicant]
Kitada et al., “Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of bcl-2 Gene Expression”, Antisense Research and Development, vol. 4, 1994, pp. 71-79 (9 pages). [cited by applicant]
Korbling et al., “Allogeneic Blood Stem Cell Transplantation: Peripheralization and Yield of Donor-Derived Primitive Hematopoietic Progenitor Cells (CD34+ Thy-Idim) and Lymphoid Subsets, and Possible Predictors of Engra… [cited by applicant]
Krosl et al., “In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein”, Nature Medicine, vol. 9, No. 11, Nov. 2003, pp. 1428-1432, DOI: 10.1038/nm951 (5 pages). [cited by applicant]
Lang et al., “Mechanisms and Significance of Erypotosis, the Suicidal Death of Erythrocytes”, Blood Purification, vol. 33, 2012, pp. 125-130, DOI: 10.1159/00034163 (6 pages). [cited by applicant]
Laurenti et al., “Hematopoietic Stem Cell Function and Survival Depend on c-Myc and N-Myc Activity”, Cell Stem Cell, vol. 3, 2008, pp. 611-624, DOI: 10.1016/j.stem.2008.09.005 (14 pages). [cited by applicant]
Levesque et al., “The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization”, Leukemia, vol. 24, 2010, pp. 1979-1992, DOI: 10.1038/leu.2010.214 (14 pages). [cited by applicant]
Li et al., “Reconstitution of functional human B lymphocytes in NOD/SC ID mice engrafted with ex vivo expanded CD34+ cord blood cells”, Experimental Hematology, vol. 30, 2002, pp. 1036-1043 (8 pages). [cited by applicant]
Littlewood et al., “A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins”, Nucleic Acids Research, vol. 23, No. 10, 1995, pp. 1686-1690 (5 pages). [cited by applicant]
MacPherson et al., “Activity-Dependent Gene Regulation in Conditionally-Immortalized Muscle Precursor Cell Lines,” Journal of Cellular Biochemistry, vol. 91, No. 4, 2004, pp. 821-839, DOI: 10.1002/jcb. 10784 (19 pages). [cited by applicant]
McCarthy, Nicola, “Underground movement”, Nature Reviews: Cancer, vol. 7, Nov. 2007, DOI: 10.1038/nrc2257 (1 page). [cited by applicant]
McNiece et al., “Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer”, Hematology and Cell Therapy, vol. 41, No. 2, 1999, pp. 82-86 DOI: 10.1007/s00282-999-0082-y (6 pages). [cited by applicant]
Melkonyan et al., “Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO)”, Nucleic Acids Research, vol. 24, No. 21, 1996, pp. 4356-4357, DOI: 10.1093/nar/24.21.4356 (2 pages). [cited by applicant]
Merino et al., “Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes”, The EMBO Journal, vol. 13, No. 3, 1994, pp. 683-691, DOI: 10.1002/j.1460-2075.1994.tb06307.x (9 pages). [cited by applicant]
Mi Harada et al., “Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells”, Nature Biotechnology, vol. 24, No. 10, 2006, pp. 1255-1256, DOI: 10.1038/nbt1245 (2 pages). [cited by applicant]
Miller et al., “Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability”, Proceedings of the National Academy of Sciences USA, vol. 94, Dec. 1997, pp. 13648-… [cited by applicant]
Moore et al., “In Vitro Maintenance of Highly Purified, Transplantable Hematopoietic Stem Cells”, Blood, vol. 89, No. 12, 1997, pp. 4337-4347, DOI: 10.1182/blood. V89. 12.4337 (12 pages). [cited by applicant]
Mooslehner et al., “Retroviral Integration Sites in Transgenic Mov Mice Frequently Map in the Vicinity of Transcribed DNA Regions”, Journal of Virology, vol. 64, 1990, pp. 3056-3058, DOI: 10.1128/jvi.64.6.3056-3058. 199… [cited by applicant]
Muchmore et al., “X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death”, Nature, vol. 381, May 23, 1996, pp. 335-341, DOI: 10.1038/381335a0 (7 pages). [cited by applicant]
Murphy et al., “Id2 Is Dispensable for Myc-Induced Epidermal Neoplasia”, Molecular and Cellular Biology, vol. 24, No. 5, Mar. 2004, pp. 2083-2090, DOI: 10.1128/MCB.24.5.2083-2090.2004 (8 pages). [cited by applicant]
Notice of Acceptance for AU 2009246876 dated Mar. 19, 2015 (3 pages). [cited by applicant]
Notice of Acceptance for AU 2009274172 dated Aug. 3, 2015 (2 pages). [cited by applicant]
Notice of Acceptance for AU 2012216462 dated Apr. 10, 2015 (2 pages). [cited by applicant]
Notice of Supplementary European Search Report for EP 06826025.6 dated Sep. 1, 2009 (3 pages). [cited by applicant]
Notification of Defects for IL 190946 dated May 14, 2015, English Translation Only (2 pages). [cited by applicant]
Notification of Defects for IL 190946 dated Jul. 3, 2012, English Translation Only (1 page). [cited by applicant]
Notification of Defects for IL 200919 dated Jan. 17, 2013 (4 pages). [cited by applicant]
Notification of Defects for IL 208810 dated Jan. 2, 2013, English Translation Only (4 pages). [cited by applicant]
Notification of Defects for IL 209343 dated Aug. 14, 2012 (3 pages). [cited by applicant]
Notification of Defects for IL 209968 dated Aug. 21, 2012 (4 pages). [cited by applicant]
Notification of Defects for IL 265409 dated Jun. 22, 2020 (8 pages). [cited by applicant]
Notification of Defects for IL 272532 dated Jun. 8, 2020 (8 pages). [cited by applicant]
Notification of Detects for IL 200919 dated Dec. 5, 2011, English Translation Only (2 pages). [cited by applicant]
Office Action for EU 201001762/28 dated Oct. 16, 2013, English Translation Only (1 page). [cited by applicant]
Office Action for IL 190946 dated Apr. 22, 2013, English Translation Only (1 page). [cited by applicant]
Office Action for IL 200919 dated May 19, 2014, English Translation Only (3 pages). [cited by applicant]
Office Action for IL 208810 dated Jan. 13, 2015, English Translation Only (3 pages). [cited by applicant]
Office Action for IL 208810 dated Jun. 27, 2018 (2 pages). [cited by applicant]
Office Action for IL 209968 dated Jan. 2, 2014, English Translation Only (2 pages). [cited by applicant]
Office Action for IL 232432 dated Mar. 8, 2015, English Translation Only (3 pages). [cited by applicant]
Office Action for IL 241192 dated Jul. 30, 2018 (6 pages). [cited by applicant]
Office Action for IL 256512 dated Jul. 29, 2018 (5 pages). [cited by applicant]
Office Action for KR 10-2008-7011791 dated Jan. 15, 2014 (6 pages). [cited by applicant]
Office Action for KR 10-2008-7011791 dated May 28, 2013 (6 pages). [cited by applicant]
Office Action for KR 10-2009-7021320 dated Jul. 29, 2011 (7 pages). [cited by applicant]
Office Action for KR 10-2009-7021320 dated Sep. 18, 2012 (11 pages). [cited by applicant]
Reasons for Rejection for JP 2016-501117 dated Nov. 15, 2017 (9 pages). [cited by applicant]
Reasons for Rejection for JP 2018-017287 dated Apr. 18, 2019 (13 pages). [cited by applicant]
Reasons for Rejection for JP 2019-006759 dated Aug. 6, 2020 (4 pages). [cited by applicant]
Reasons for Rejection for JP 2019-025374 dated Mar. 9, 2020 (8 pages). [cited by applicant]
Reasons for Rejection for JP 2019-512193 dated Sep. 30, 2019 (8 pages). [cited by applicant]
Reasons for Rejection for JP 2019-529651 dated Jul. 15, 2020 (6 pages). [cited by applicant]
Reasons of Refusal for JP 2012-221023 dated Jun. 24, 2014, English Translation Only (2 pages). [cited by applicant]
Reexamination Notification for CN 201380048261.4 dated May 11, 2021 (16 pages). [cited by applicant]
Refaeli et al., “The B Cell Antigen Receptor and Overexpression of MYC Can Cooperate in the Genesis of B-Cell Lymphomas”, PLOS Biology, vol. 6, Issue 6, e152, 2008, pp. 1208-1225, DOI: 10.1371 /journal.pbio.0060152 (18 … [cited by applicant]
Refaeli et al., “The protooncogene MYC can break B cell tolerance”, Proceedings of the National Academy of Sciences, vol. 102, No. 11, Mar. 2005, pp. 4097-4102, DOI: 10.1073/pnas.0409832102 (6 pages). [cited by applicant]
Richter et al., “Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression”, Journal of Hematology, vol. 88, No. 12, 2003, pp. 1336-1347 (1… [cited by applicant]
Roh et al., “Transgenic Mice for ere-Inducible Overexpression of the Oncogenes c-MYC and Pim-1 in Multiple Tissues”, Genesis: The Journal of Genetics and Development, vol. 44, 2006, pp. 447-453, DOI: 10.1002/dvg.20235 (… [cited by applicant]
Rosenwald et al., “Increased expression of eukaryotic translation initiation factors elF-4E and elF-2alpha in response to growth induction by c-myc”, Proceedings of the National Academy of Sciences USA, vol. 90, 1993, D… [cited by applicant]
Rubinstein et al., “Ex Vivo Interleukin-12-Priming During CDS+ T Cell Activation Dramatically Improves Adoptive T Cell Transfer Antitumor Efficacy in a Lymphodepleted Host”, Journal of the American College of Surgeons, … [cited by applicant]
Rudolph et al., “Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation”, Oncogene, vol. 20, 2001, pp. 1164-1175 (12 pages). [cited by applicant]
Satoh et al., “Roles for c-Myc in Self-renewal of Hematopoietic Stem Cells”, The Journal of Biological Chemistry, vol. 279, No. 24, 2004, pp. 24986-24993, DOI: 10.1074/jbc. M400407200 (9 pages). [cited by applicant]
Sauer, Brian “Inducible Gene Targeting in Mice Using the Cre/lox System”, Methods: A Companion to Methods in Enzymology, vol. 14, No. ME980593, 1998, pp. 381-392 (12 pages). [cited by applicant]
Schiedlmeier et al., “High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation”, Blood, vol. 101, No. 5, Mar.… [cited by applicant]
Schmidt et al., “Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: A pre-B-cell lymphoma model”, Proceedings of the National Academy of Sciences, vol. 85, Aug. 1988, pp. 6047-6051 (5 … [cited by applicant]
Schneider et al., “Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90”, Proceedings of the National Academy of Sciences, Cell Biology, vol. 93, Dec. 1996, pp. 14536-14541 (6 … [cited by applicant]
Schroy et al., “A Simple Method for Freezing and Thawing Cultured Cells,” Methods in Cell Science (formerly known as TCA Manual), vol. 2, No. 1, 1976, pp. 309-310 (2 pages). [cited by applicant]
Schwarze et al., “In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA”, Trends in Pharmacological Sciences, vol. 21, Feb. 2000, pp. 45-48 (4 pages). [cited by applicant]
Schwarze et al., “Protein transduction: unrestricted delivery into all cells?” Trends in Cell Biology, vol. 10, Jul. 2000, pp. 290-295 (6 pages). [cited by applicant]
Second Office Action for CN 200680045545.8 dated Sep. 15, 2011, English Translation Only (9 pages). [cited by applicant]
Second Office Action for CN 200880015602.7 dated Oct. 31, 2012 (1 O pages). [cited by applicant]
Second Office Action for CN 200980126312.4 dated Aug. 28, 2012 (12 pages). [cited by applicant]
Second Office Action for CN 200980127166.7 dated Jun. 10, 2013, English Translation Only (1 page). [cited by applicant]
Second Office Action for CN 2014104 79865.2 dated Jul. 5, 2016 (6 pages). [cited by applicant]
Second Office Action for CN 201480026147.6 dated Apr. 20, 2017 (11 pages). [cited by applicant]
Second Office Action for CN 201480026500.0 dated Apr. 27, 2018 (5 pages). [cited by applicant]
Second Office Action for CN 201780082261.4 dated Feb. 26, 2021 (5 pages). [cited by applicant]
Seibutsugaku Jiten (Dictionary of Biology), Iwanami Shoten, The 4th edition, 1997, p. 1396 (2 pages). [cited by applicant]
Siebenlist et al., “ [cited by applicant]
Silva et al., “Erythropoietin Can Promote Erythroid Progenitor Survival by Repressing Apoptosis Through Bel-XL and Bcl-2”, Blood, vol. 88, No. 5, Sep. 1, 1996, pp. 1576-1582 (8 pages). [cited by applicant]
Sipione et al., “Modeling Brain Pathologies Using Neural Stem Cells”, Methods in Molecular Biology, vol. 198, 2002, pp. 245-262 (18 pages). [cited by applicant]
Snyder et al., “Regulation of NMDA receptor trafficking by amyloid-beta”, Nature Neuroscience, 2005, vol. 8, No. 8, pp. 1051-1058, DOI: 10.1038/nn1503 (8 pages). [cited by applicant]
Soane et al., “TAT-mediated endocytotic delivery of the loop deletion Bcl-2 protein protects neurons against cell death”, Journal of Neurochemistry, vol. 95, 2005, pp. 230-243, DOI: 10.1111/j.1471-4159.2005.03359.x (14 … [cited by applicant]
Song, “Cloning and expression of PTD-BDNF fusion gene and purification of expressed product”, Bioengineering Pharmaceutical Research and Practice, Anhui Science and Technology Press, 1st Ed., Feb. 2009, pp. 200-201 (3 p… [cited by applicant]
Stein et al., “TAT-MYC Recombinant Fusion Protein Enhances Hematopoietic Stem Cell Graft Performance and Immunne Cell Reconstitution after Transplantation,” Blood, vol. 130, Suppl. 1, Dec. 7, 2017, pp. 3175 (2 pages). [cited by applicant]
Stevenson et al., “HIV-1 replication is controlled at the level of T cell activation and proviral integration”, The EMBO Journal, vol. 9, No. 5, 1990, pp. 1551-1560 (10 pages). [cited by applicant]
Strasser et al., “Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2”, Letters to Nature, vol. 348, 1990, pp. 331-333 (3 pages). [cited by applicant]
Sunyer, J. Oriol, “Evolutionary and Functional Relationships of B Cells from Fish and Mammals: Insights into their Novel Roles in Phagocytosis and Presentation of Particulate Antigen”, Infectious Disorders—Drug Targets,… [cited by applicant]
Supplementary European Search Report for EP 08743862.8 dated Mar. 31, 2010 (1 page). [cited by applicant]
Taguchi et al., “Nuclear trafficking of macromolecules by an oligopeptide derived from Vpr of human immunodeficiency virus type-1 ”, Biochemical and Biophysical Research Communications, vol. 320, No. 1, 2004, pp. 18-26 … [cited by applicant]
Takahashi et al., Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors, Cell, vol. 126, Aug. 2006, pp. 663-676, DOI: 10.1016/j.cell.2006.07.024 (14 pages). [cited by applicant]
Theis et al., “Expression of the myc/His-Tagged Human Peptide Transporter hPEPT1 in Yeast for Protein Purification and Functional Analysis”, Protein Expression and Purification, 2001, vol. 22, pp. 436-442 (7 pages). [cited by applicant]
Third Office Action for CN 200680045545.8 dated Feb. 15, 2015, English Translation Only (4 pages). [cited by applicant]
Third Office Action for CN 200880015602.7 dated May 9, 2013 (13 pages). [cited by applicant]
Third Office Action for CN 200980127166. 7 (106417-0109) dated Apr. 11, 2014 (6 pages). [cited by applicant]
Third Office Action for CN 201410168106.2 dated Nov. 28, 2016 (11 pages). [cited by applicant]
Examination Report for EP 14 779483.8 dated Jun. 28, 2019 (4 pages). [cited by applicant]
Examination Report for EP 14 779483.8 dated Jun. 29, 2018 (4 pages). [cited by applicant]
Examination Report for EP 14 779483.8 dated Oct. 16, 2017 (4 pages). [cited by applicant]
Examination Report for EP 18154875.1 dated Sep. 6, 2019 (4 pages). [cited by applicant]
Examination Report for In 2048/DELNP/2011 dated Sep. 15, 2016 (9 pages). [cited by applicant]
Examination Report for In 3332/DELNP/2008 dated Aug. 23, 2013 (6 pages). [cited by applicant]
Examination Report for In 634/DELNP/2011 dated Jun. 8, 2017 (10 pages). [cited by applicant]
Examination Report for In 6624/DELNP/2014 dated Sep. 27, 2018 (4 pages). [cited by applicant]
Examination Report for In 9033/DELNP/2010 dated May 19, 2017 (11 pages). [cited by applicant]
Examination Report for In 9205/DELNP/2015 dated Nov. 28, 2019 (8 pages). [cited by applicant]
Examination Report for In 9206/DELNP/2015 dated Dec. 26, 2019 (6 pages). [cited by applicant]
Examination Report No. 1 for AU 2009285547 dated Jul. 25, 2011 (2 pages). [cited by applicant]
Examination Report No. 1 for AU 2013292330 dated Sep. 6, 2017 (3 pages). [cited by applicant]
Examination Report No. 1 for AU 2014202016 dated May 12, 2015 (3 pages). [cited by applicant]
Examination Report No. 1 for AU 2014249200 dated Mar. 15, 2019 (4 pages). [cited by applicant]
Examination Report No. 1 for AU 2016203892 dated Apr. 12, 2017 (3 pages). [cited by applicant]
Extended European Search Report for EP 06826025.6 dated Aug. 13, 2009 (8 pages). [cited by applicant]
Extended European Search Report for EP 09747016.5 dated May 30, 2012 (8 pages). [cited by applicant]
Extended European Search Report for EP 09800871.7 dated Jun. 24, 2011 (5 pages). [cited by applicant]
Extended European Search Report for EP 09810692.5 dated Jul. 11, 2011 (5 pages). [cited by applicant]
Extended European Search Report for EP 12187077.8 dated Mar. 25, 2013 (7 pages). [cited by applicant]
Extended European Search Report for EP 12187097.6 dated Mar. 27, 2013 (8 pages). [cited by applicant]
Extended European Search Report for EP 13188850.0 dated May 27, 2014 (8 pages). [cited by applicant]
Extended European Search Report for EP 13820331.0 dated Oct. 10, 2016 (9 pages). [cited by applicant]
Extended European Search Report for EP 14 778538.0 dated Sep. 29, 2016 (17 pages). [cited by applicant]
Extended European Search Report for EP 14 779483.8 dated Dec. 23, 2016 (5 pages). [cited by applicant]
Extended European Search Report for EP 15175802.6 dated Dec. 14, 2015 (7 pages). [cited by applicant]
Extended European Search Report for EP 20212922.7 dated May 26, 2021 (7 pages). [cited by applicant]
Extended European Search Report for EP 21170329.3 dated Oct. 22, 2021 (10 pages). [cited by applicant]
Extended Search Report for EP 17920607.3 dated Dec. 11, 2019 (7 pages). [cited by applicant]
Extended Search Report for EP 19157513.3 dated Apr. 1, 2019 (13 pages). [cited by applicant]
Fanidi et al., “Cooperative interaction between c-myc and bcl-2 proto-oncogenes”, Nature, vol. 359, Oct. 8, 1992, pp. 554-556 (3 pages). [cited by applicant]
Felsher et al., “Reversible Tumorigenesis by MYC in Hematopoietic Lineages”, Molecular Cell, vol. 4, Aug. 1999, pp. 199-207 (9 pages). [cited by applicant]
Fifth Office Action for CN 200980126312.4 dated Jan. 22, 2014, English Translation Only (3 pages). [cited by applicant]
Final Rejection for KR 10-2009-7021320 dated May 29, 2013 (6 pages). [cited by applicant]
Final Rejection for KR 10-2010-7028384 dated Mar. 28, 2017 (6 pages). [cited by applicant]
First Office Action for CN 200680045545.8 dated Dec. 31, 2010, English Translation Only (8 pages). [cited by applicant]
First Office Action for CN 200880015602.7 dated Jan. 31, 2012 (16 pages). [cited by applicant]
First Office Action for CN 200980126312.4 dated Jan. 30, 2012 (14 pages). [cited by applicant]
First Office Action for CN 200980127166.7 dated Dec. 5, 2012 (4 pages). [cited by applicant]
First Office Action for CN 201380048261.4 dated May 24, 2018 (17 pages). [cited by applicant]
First Office Action for CN 2014104 79685.2 dated Nov. 17, 2015 (12 pages). [cited by applicant]
First Office Action for CN 201510760532X dated May 11, 2018 (13 pages). [cited by applicant]
Foreign Action other than Search Report on EP 19157513.3 DTD Mar. 3, 2022. [cited by applicant]
Foreign Action other than Search Report on JP 2021-037508 DTD Mar. 31, 2022. [cited by applicant]
Foreign Search Report and Written Opinion issued for SG Appl. Ser. No. 10201707390V dated Oct. 13, 2021 (9 pages). [cited by applicant]
Fourth Office Action for CN 200880015602.7 dated Nov. 11, 2013, English Translation Only (6 pages). [cited by applicant]
Fourth Office Action for CN 201410168106.2 dated Jun. 22, 2017 (8 pages). [cited by applicant]
Futaki, Chemistry and Biology (Kagaku to Seibutsu), vol. 43, No. 10, Oct. 1, 2005, pp. 649-653. [cited by applicant]
Gandarillas et al., “c-Myc promotes differentiation of human epidermal stem cells”, Genes & Development, vol. 11, 1997, pp. 2869-2882 (15 pages). [cited by applicant]
Gauss et al., “DEAE-dextran enhances electroporation of mammalian cells”, Nucleic Acids Research, vol. 20, No. 24, 1992, pp. 6739-6740 (2 pages). [cited by applicant]
Goeddel et al., “Direct expression in [cited by applicant]
Goeddel et al., “Synthesis of human fibroblast interferon by [cited by applicant]
Gross et al., “BCL-2 family members and the mitochondria in apaptosis”, Genes & Development, vol. 13, No. 15, Aug. 1999, pp. 1899-1911 (14 pages). [cited by applicant]
Grumont et al., “The Mitogen-Induced Increase in T Cell Size Involves PKC and NFAT Activation of Rel/NF-kappaB-Dependent c-myc Expression”, Immunity, vol. 21, Jul. 2004, pp. 19-30 (12 pages). [cited by applicant]
Guzman et al., “Preferential induction of apoptosis for primary human leukemic stem cells”, Proceedings of the National Academy of Sciences, vol. 99, No. 25, Dec. 10, 2002, pp. 16220-16225, DOI: 10.1073/pnas.252462599 (… [cited by applicant]
Habib et al., “Myc Stimulates B lymphocyte differentiation and amplifies calcium signaling”, The Journal of Cell Biology, vol. 179, No. 4, 2007, pp. 717-731, DOI: 10.1083/jcb.200704173 (11 pages). [cited by applicant]
Hann et al., “Proteins Encoded by the Human c-myc Oncogene: Differential Expression in Neoplastic Cells”, Molecular and Cellular Biology, vol. 4, No. 11, Nov. 1984, pp. 2486-2497 (12 pages). [cited by applicant]
Hiramatsu et al., “Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gamma-c-null mice model”, Blood, vol. 102, No. 3, Aug. 1, 2003, pp. 873-880 (8 pages). [cited by applicant]
Hirose et al., “Immortalization of Erythroblasts by c-MYC and BCL-XL Enables Large-Scale Erythrocyte Production from Human Pluripotent Stem Cells”, Stem Cell Reports, vol. 1, Dec. 17, 2013, DD. 99-508 (1 O paqes). [cited by applicant]
Ho et al., “Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo”, Cancer Research, vol. 61, Jan. 15, 2001, pp. 474-477 (5 pages). [cited by applicant]
Hoffman, Ronald, “Progress in the development of systems for in vitro expansion of human hematopoietic stem cells”, Current Opinion in Hematology, vol. 6, No. 3, 1999, p. 184 (14 pages). [cited by applicant]
Horton et al., “Continuous MLL-ENL Expression Is Necessary to Establish a ‘Hox Code’ and Maintain Immortalization of Hematopoietic Progenitor Cells”, Cancer Research, vol. 65, No. 20, Oct. 15, 2005, pp. 9245-9252, DOI: … [cited by applicant]
Hoshimaru et al., “Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene”, Proceedings of the National Academy of Sciences USA, Neuro… [cited by applicant]
Howard et al., “Transplantation of apoptosis-resistant embryonic stem cells into the injured rat spinal cord”, Somatosensory and Motor Research, vol. 22, No. 1/2, Mar./Jun. 2005, pp. 37-44, DOI: 10.1080/0899022050008490… [cited by applicant]
Huang et al., “Dynamic Regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse”, European Journal of Immunology, vol. 38, No. 2, 2008, pp. 342-349, DOI: 10.1002… [cited by applicant]
Huang et al., “Negative Control of the Myc Protein by the Stress-Responsive Kinase Pak2”, Molecular and Cellular Biology, vol. 24, No. 4, Feb. 2004, pp. 1582-1594, Doi: 10.1128/MCB.24.4.1582-1594.2004 (13 pages). [cited by applicant]
Huettner et al., “Reversibility of acute B-cell leukaemia induced by BCR-ABL 1 ”, Nature Genetics, vol. 24, Jan. 2000, pp. 57-60 (4 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US09/55443 dated Mar. 1, 2011 (6 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2006/040379 dated Apr. 23, 2008 (5 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2008/056896 dated Sep. 15, 2009 (4 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2008/082263 dated May 4, 201 O (6 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2009/003105 dated Nov. 17, 201 O (6 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2009/051242 dated Jan. 25, 2011 (6 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2009/055443 dated Mar. 1, 2011 (6 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2013/051384 dated Jan. 29, 2015 (1 O pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2014/022971 dated Sep. 24, 2015 (8 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2014/022977 dated Sep. 15, 2015 (9 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2017/045336 dated Feb. 13, 2020 (8 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2017/064206 dated Jun. 13, 2019 (13 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2020/027070 dated Oct. 21, 2021 (9 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2006/040379 dated Sep. 24, 2007 (7 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2008/056896 dated Aug. 14, 2008 (5 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2008/082263 dated Jun. 25, 2009 (8 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2009/003105 dated Jan. 15, 2010 (9 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2009/051242 dated Feb. 19, 2010 (9 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2009/055443 dated Jun. 30, 2010 (11 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2013/051384 dated Nov. 13, 2013 (15 pages). [cited by applicant]